Search Within

Mark Andrew Dickson

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (39)
Groups
  1. Department of Medicine (87)
  2. Hematologic Malignancies, Division of (87)
  3. Sarcoma Service (87)
  4. Solid Tumor Oncology Division (87)
  5. GSK Faculty (71)
  6. Epidemiology and Biostatistics (62)

More Groups

People
  1. Sandra D'Angelo (84)
  2. William Tap (72)
  3. Mary Keohan (70)
  4. Mrinal Gounder (68)
  5. Ping Chi (55)
  6. Li-Xuan Qin (50)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (7)
  4. 2022 (14)
  5. 2021 (2)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (44)
  2. Clinical Cancer Research (9)
  3. Annals of Oncology (6)
  4. Nature Communications (3)
  5. The Oncologist (3)
  6. JAMA Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (45)
  2. American Association for Cancer Research (11)
  3. Oxford University Press (9)
  4. Elsevier Inc. (5)
  5. Nature Publishing Group (4)
  6. American Medical Association (2)

More Publishers

Results (87)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bradic, M.; Desir, R.; Kelly, C. M.; Movva, S.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; Clark, C.; Counihan, O.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma
    Journal Article

    Gleason, C. E.; Dickson, M. A.; Klein, M. E.; Antonescu, C. R.; Gularte-Mérida, R.; Benitez, M.; Delgado, J. I.; Kataru, R. P.; Tan, M. W. Y.; Bradic, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Kelly, C.; Movva, S.; Nacev, B. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save